Approvals

Lilly’s breast cancer drug Verzenio secures another approval in US

Eli Lilly and Company has secured additional approval from the US Food and Drug Administration (FDA) for Verzenio (abemaciclib) as initial treatment for advanced breast cancer.

FDA approves KemPharm’s Apadaz for short-term pain management

KemPharm has secured approval from the US Food and Drug Administration (FDA) for its opioid painkiller, Apadaz, for the short-term management of acute pain.

Mylan bags FDA’s tentative approval for fixed-dose HIV combo therapy

Mylan has secured tentative approval from the US Food and Drug Administration (FDA) for its fixed-dose HIV combination therapy Dolutegravir/Emtricitabine/Tenofovir Alafenamide (DTG/FTC/TAF 50 mg/200mg/25mg) tablets.

AstraZeneca’s Imfinzi wins FDA approval for lung cancer treatment

AstraZeneca's immunotherapy Imfinzi (durvalumab) has secured approval from the US Food and Drug Administration (FDA) for unresectable stage III non-small cell lung cancer (NSCLC).

GSK’s Fluarix Tetra wins European approval for expanded indication

GSK has secured European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older.

Janssen’s Erleada wins FDA nod for nonmetastatic prostate cancer

Janssen Pharmaceutical’s androgen receptor inhibitor Erleada (apalutamide) has been approved by the US Food and Drug Administration (FDA) for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).

Novartis’ Cosentyx label expanded to include scalp psoriasis

Novartis has secured approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab) label update to include moderate-to-severe scalp psoriasis.

FDA grants breakthrough therapy designation for GSK’s meningitis B vaccine Bexsero

GlaxoSmithKline has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for its meningitis B vaccine Bexsero [Meningococcal group B Vaccine (rDNA, component, adsorbed)] for the development of the vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age.

Capricor gets FDA RMAT designation for CAP-1002 to treat Duchenne muscular dystrophy therapy

The US Food and Drug Administration (FDA) has granted the regenerative medicine advanced therapy (RMAT) designation for Capricor Therapeutics’ investigational cell therapy for the treatment, CAP-1002, to treat Duchenne muscular dystrophy.